Contribute Try STAT+ Today

Amarin failed to convince a federal appeals court to revive key patents covering its heart drug Vascepa. The decision, announced Thursday, exposes the company’s only drug to generic competition in the U.S.

The ruling comes just one day after oral arguments and affirms an earlier court decision that some patents covering Vascepa were “obvious” and thus unenforceable. The ruling is a victory for Hikma Pharmaceuticals and Dr. Reddy’s Laboratories, two companies planning to sell generic versions of Vascepa.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy